Ravenna
Ravenna
Ravenna, RA, Italy14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 2 | 2026-09-09 | NCT06578559 | |
| Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-19 | NCT02390869 | |
| IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, disease, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-08-14 | NCT06713837 | |
| Master Framework For Relapse or Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-08-14 | NCT06459024 | |
| Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance | Actinomycetales infectious disease, Bacterial Infections and Mycoses, COVID-19, Clostridium infectious disease, Coronaviridae Infections, Corynebacterium Infections, DNA Virus Infections, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, Varicella Zoster Virus Infection, bacterial infectious disease, diphtheria, follicular lymphoma, gram-positive bacterial infections, herpes zoster, immune system disorder, immunoproliferative disorder, lung disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, tetanus, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-06-26 | NCT06070961 | |
| A New Crowding Indicator in the Emergency Department | Disease Attributes, Emergencies, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Not stated | 2026-05-20 | NCT07111624 | |
| Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Not stated | 2026-04-22 | NCT07363252 | |
| ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients | CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, relapsing-remitting multiple sclerosis | Active, not recruiting | Not stated | 2026-04-13 | NCT06345157 | |
| Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | Non-small-cell Lung Cancer Patients | Active, not recruiting | Phase 2 | 2026-02-09 | NCT03896074 | |
| FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2025-12-08 | NCT06733038 | |
| Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-04-10 | NCT04300101 | |
| "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-04-09 | NCT06919393 | |
| Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Active, not recruiting | Not stated | 2025-01-29 | NCT06798805 | |
| This Will Be an Observational, Exploratory Study Targeting a Population of Subjects with Diabetes from 4 Different Geographical Areas of Emilia- Romagna. | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Active, not recruiting | Not stated | 2024-10-15 | NCT06639100 |